Ginwa Biotech: Signs Strategic Cooperation Agreement with Watson Biotech Hong Kong to Expand Overseas Market for Influenza Vaccine Subunit

Zhonghui Bioscience announced that the company has entered into a strategic cooperation agreement with Watson Bio Hong Kong Limited regarding the overseas market expansion of subunit influenza vaccines. According to the strategic cooperation agreement, both parties will deepen cooperation in overseas market registration, sales, and commercialization of products developed by the group. The core product of this overseas expansion is the trivalent subunit influenza vaccine independently developed by the group. The product was granted market approval in January 2026, making it the first and only trivalent subunit influenza vaccine in China that is suitable for the entire population aged 6 months and above.